Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.

Bipolar Disorder Clinical Trial

— EMMY  

Official title:

A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00521365
• Other study ID #: D1443L00017
• Status: Completed
• Phase: Phase 4
• First received: August 24, 2007
• Last updated: June 12, 2012
• Start date: May 2008
• Est. completion date: August 2009

Study information

• Verified date: March 2012
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Mexico: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The primary purpose of the study is to assess the efficacy of Quetiapine extended release 600mg per day either as monotherapy or combined therapy in the treatment of patients with mania associated to Bipolar disorder. This trial will also assess the life quality and productivity loss improvement for patients from baseline to day 21.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 88
• Est. completion date: August 2009
• Est. primary completion date: August 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients with type I Bipolar Disorder in Manic phase according to standard scales and physician criteria.

• Patients of both genders, aged 18-65 years old being at the first episode

• Patients with chronic Bipolar Disorder with at least one previous manic episode 6 months before inclusion, that based on the physician experience are in a manic episode at study entry quality

Exclusion Criteria:

• Psychoactive substance or alcohol abuse or dependence, forbidden medication, pregnancy, rapid cycling patients, intolerance to Quetiapine, clinically severe disease, unstable Diabetes Mellitus, neutropenia, other laboratory abnormalities

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Affective Disorders, Psychotic
• Bipolar Affective Psychosis
• Bipolar Disorder
• Disease
• Mania
• Manic Disorder
• Manic State

Intervention

Drug:
• Quetiapine 600mg
300 mg quetiapine fumarate tablets for oral use. Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day.

Locations

Country	Name	City	State
Mexico	Research Site	Durango
Mexico	Research Site	Guadalajara	Jalisco
Mexico	Research Site	Merida	Yucatan
Mexico	Research Site	Mexico	DF
Mexico	Research Site	Monterrey	Nuevo Leon
Mexico	Research Site	San Luis Potosi
Mexico	Research Site	San Pedro Garza García	Nuevo Leon

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to End of Treatment (Day 21)	Change in the YMRS total score from baseline to Final Visit or Last Observation Carried Forward (LOCF), modified intention to treat (mITT) population. YMRS questionnaire has 11 items with scale range 0 to 4 for 7 items and 0 to 8 for 4 items. 0=normal; 4 or 8=most abnormal. Total possible score is 0 - 60.	Baseline and 3 weeks	No
Secondary	Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Visit 2.	Change in the YMRS total score from baseline to visit 2 (1 week) ,. YMRS questionnaire has 11 items with scale range 0 to 4 for 7 items and 0 to 8 for 4 items. 0=normal; 4 or 8=most abnormal. Total possible score is 0-60.	Baseline and 1 week	No
Secondary	Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Visit 3	Change in the YMRS total score from baseline to visit 3(2 weeks). YMRS questionnaire has 11 items with scale range 0 to 4 for 7 items and 0 to 8 for 4 items. 0=normal; 4 or 8=most abnormal. Total possible score is 0-60.	Baseline and 2 weeks	No
Secondary	Number of Participants With Young Mania Rating Scale (YMRS) Response at Final Visit or Last Observation Carried Forward (LOCF)	Number of participants that had Young Mania Rating Scale (YMRS) response at Final Visit or Last Observation Carried Forward (LOCF). A patient is scored as responder if the change from inclusion shows a reduction of 6 points in the YMRS total score.; YMRS questionnaire has 11 items with scale range 0 to 4 for 7 items and 0 to 8 for 4 items. 0=normal; 4 or 8=most abnormal. Total possible score is 0 - 60.	21 days ± 2 days or Last Observation Carried Forward	No
Secondary	Number of Participants With Young Mania Rating Scale (YMRS) Remission at Final Visit or Last Observation Carried Forward (LOCF).	Number of participants that had Young Mania Rating Scale (YMRS) remission at Final Visit or Last Observation Carried Forward (LOCF). A patient is classified in remission if his/her final YMRS total score was =11.; YMRS questionnaire has 11 items with scale range 0 to 4 for 7 items and 0 to 8 for 4 items. 0=normal; 4 or 8=most abnormal. Total possible score is 0 - 60.	21 days ± 2 days or Last Observation Carried Forward	No
Secondary	Change in the Clinical Global Impression (CGI) Total Score From Baseline (CGI-S) to Final Visit or Last Observation Carried Forward (LOCF)(CGI-I).	Clinical Global Impression-Severity(CGI-S)is a measurement of illness severity evaluated at baseline. Clinical Global Impression-Improvement(CGI-I)is a measurement of improvement taken at Final Visit (FV) or Last Observation Carried Forward(LOCF).Change CGI Total score is assessed with next equation: CGI-I total score at FV or LOCF - CGI-S score. CGI-S Questionnaire has a scale range 0-7. 0=patients who are not assessed, 1=Normal 7=the most extremely ill patients. CGI-I Questionnaire has a scale range 0-7. 0=patients who are not assessed, 1=Very much improved; 4= No change; 7=Very much worse.	Baseline and 3 weeks	No
Secondary	Change in the Clinical Global Impression - Improvement (CGI-I) at Final Visit or Last Observation Carried Forward (LOCF).	Change in the CGI- I at Final Visit or Last Observation Carried Forward (LOCF). CGI I Questionnaire has a one item with scale range 0 to 7. 0=patients who ere not assessed, 1=Very much improved; 4= No change; 7=Very much worse.	Baseline and 3 weeks	No
Secondary	Change in the Quality of Life Questionnaire EQ5D Index From Baseline to End of the Study.	Total possible index score is 0-1(0=The worsen quality of life; 1=The best Quality of life).	Baseline and 3 weeks	No
Secondary	Change in the Quality of Life Questionnaire EQ5D Visual Analogue Scale (VAS) From Baseline to Final Visit or Last Observation Carried Forward (LOCF).	Change from baseline to Final Visit or Last Observation Carried Forward (LOCF). Quality of Life Questionnaire (EQ5D) part 2 has 1 item with continuous scale range 0 to 100. 0=The worsen Quality of Life; 100=The best Quality of life.	Baseline and 3 weeks	No
Secondary	Change in the Simpson-Angus Scale (SAS) Total Score From Baseline to Final Visit or Last Observation Carried Forward (LOCF).	Change in the Simpson-Angus Scale (SAS) total score from baseline to Final Visit or Last Observation Carried Forward (LOCF).; SAS Questionnaire has a 6 items with scale range 0 to 3 for each item.0=Normal; 3=Most abnormal. Total possible score is 0-18.	Baseline and 3 weeks	Yes
Secondary	Change in the Barnes Akathisia Rating Scale (BARS) Total Score From Baseline to Final Visit or Last Observation Carried Forward (LOCF).	Change in the BARS total score from baseline to Final Visit or Last Observation Carried Forward (LOCF). BARS Questionnaire has 4 items with scale range 0 to 3 for 3 items and 0 to 5 for 1 item. 0=Normal; 3 or 5=Most abnormal. Total possible score is 0-14.	Baseline and 3 weeks	Yes
Secondary	Change in Weight From Baseline to Final Visit or Last Observation Carried Forward (LOCF).		Baseline and 3 weeks	Yes
Secondary	Change in Waist Circumference From Baseline to Final Visit or Last Observation Carried Forward (LOCF).		Baseline and 3 weeks	Yes
Secondary	Number of Participants With >7% Increase in Weight	Number of participants with >7% increase in weight from baseline to end of study.	Baseline and 3 weeks	Yes